These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3556122)

  • 1. Effects of changes in pH, medium and inoculum size on the in vitro activity of different quinolone and fluoroquinolone antibiotics against urinary pathogens.
    Gesu GP; Eftimiadi C; Debbia E; Schito GC
    Drugs Exp Clin Res; 1987; 13(2):79-84. PubMed ID: 3556122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antibacterial activity of E-3604, a new 6-fluoroquinolone, on clinical isolates.
    Xicota MA; Coll R; Esteve M; Moros M; Parés J
    Drugs Exp Clin Res; 1987; 13(3):133-6. PubMed ID: 3622242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The post-antimicrobial suppressive effect of quinolone agents.
    Neu HC; Kumada T; Chin NX; Mandell W
    Drugs Exp Clin Res; 1987; 13(2):63-7. PubMed ID: 3107958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Variations in vitro of the efficacy of quinolones as a function of pH].
    François B; Gille Y; Schmuck N; Assenat H; Adeleine P; Davoine P
    Nephrologie; 1983; 4(6):259-62. PubMed ID: 6669186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of norfloxacin in synthetic media and human urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid.
    Shah PM; Ottnad-Walz M; Stille W
    Methods Find Exp Clin Pharmacol; 1983 Dec; 5(10):731-4. PubMed ID: 6231438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine.
    Erdogan-Yildirim Z; Burian A; Manafi M; Zeitlinger M
    Res Microbiol; 2011 Apr; 162(3):249-52. PubMed ID: 21288486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies of tigemonam: a comparison of the minimum inhibitory and minimum bactericidal concentrations (MIC vs MBC).
    Gobernado M; Cantón E
    J Chemother; 1989 May; 1 Suppl 2():36-40. PubMed ID: 2809701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of the culture medium (Isosensitest or Mueller-Hinton) on the results of antibiotics susceptibility testing and its interpretation].
    Flandrois JP; Peyret M; Zindel J
    Pathol Biol (Paris); 1991 May; 39(5):455-60. PubMed ID: 1652733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
    Jones RN; Fritsche TR; Ge Y; Kaniga K; Sader HS
    J Antimicrob Chemother; 2005 Dec; 56(6):1047-52. PubMed ID: 16239290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of six beta-lactams and six quinolones against urinary gram negative bacteria.
    Galante D; Esposito S; Barba D
    Boll Ist Sieroter Milan; 1986; 65(5):361-7. PubMed ID: 3828090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to ten different fluoroquinolone antibiotics following in vitro exposures to nalidixic acid.
    Barry AL; Gardiner RV; Packer RR
    Diagn Microbiol Infect Dis; 1987 Jan; 6(1):77-9. PubMed ID: 3802748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with ciprofloxacin in vitro and in vivo.
    Giamarellou H; Efstratiou A; Tsagarakis J; Petrikkos G; Daikos GK
    Arzneimittelforschung; 1984; 34(12):1775-8. PubMed ID: 6442151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative activity of twelve 4-quinolone antimicrobials and sulphadiazine against Neisseria meningitidis.
    Felmingham D; Wall RA
    Drugs Exp Clin Res; 1985; 11(7):427-9. PubMed ID: 3939218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of pefloxacin compared to that of quinolones and other antimicrobial agents.
    Neu HC; Chin NX; Labthavikul P; Saha G
    Chemioterapia; 1984 Aug; 3(4):235-41. PubMed ID: 6241847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of glucose added urine on the in vitro antimicrobial activity of various antibiotics.
    Gönüllü N; Küçükbasmaci O; Büyükbaba-Boral O; Anğ-Küçüker M
    Indian J Med Res; 2008 Nov; 128(5):663-5. PubMed ID: 19179689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of changes in pH, medium, and inoculum size on the in vitro activity of amifloxacin against urinary isolates of Staphylococcus saprophyticus and Escherichia coli.
    Iravani A; Welty GS; Newton BR; Richard GA
    Antimicrob Agents Chemother; 1985 Apr; 27(4):449-51. PubMed ID: 3890724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.